Sign In
Buy IMAB
$4.63
+0 (+0%)
At Close: Apr 14, 2026
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
08:00am, Friday, 30'th Jul 2021
Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease SHANGHAI and GAITHERSBURG,
This Biotech Stock Is Too Cheap to Ignore
09:40am, Thursday, 29'th Jul 2021
Wall Street's short attention span has created an attractive entry point in this once-loved biotech.
I-Mab Stock Moves Higher As IND For Mid-Stage Efineptakin Cancer Trial Accepted By China
10:50am, Wednesday, 28'th Jul 2021
The National Medical Products Administration (NMPA) of China has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial of efineptakin alfa for advanced solid tumors. The tri
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
07:15am, Wednesday, 28'th Jul 2021
Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase 1b/2 trial in South Korea Efineptakin alfa in patients with GBM showed a 83.3% survival rati
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
08:35am, Tuesday, 27'th Jul 2021
SHANGHAI and GAITHERSBURG, Md. , July 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commerciali
ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile ABL503 currently in Phase 1 trial to evaluate the safety, tolerabili
SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializat
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
08:00am, Thursday, 01'st Jul 2021
First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors China sites to join the dose expansion part of the study to accelerate TJ- CD4
I-Mab Honored with Top Rankings by Institutional Investor
08:00am, Wednesday, 30'th Jun 2021
SHANGHAI and GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializa
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
08:00am, Friday, 25'th Jun 2021
SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializa
I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
08:00am, Wednesday, 02'nd Jun 2021
SHANGHAI and GAITHERSBURG, Md., June 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializat
I-Mab Appoints Ruyi He and Rong Shao to Board of Directors
08:00am, Tuesday, 01'st Jun 2021
SHANGHAI and GAITHERSBURG, Md., June 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializat
I-Mab Announces Upcoming Participation at June Conferences
08:00am, Thursday, 27'th May 2021
SHANGHAI and GAITHERSBURG, Md., May 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat
Pharmaron, I-Mab And Burning Rock Get Investor Validation From MSCI
06:38pm, Friday, 21'st May 2021
MSCI's addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential. Inclusion typically represents validation for a company's products and outl
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings
06:17am, Thursday, 20'th May 2021
I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG's (OTC: RHHBY) Tecentriq (atezolizumab) in patients with advanced canc
